

Zura Bio Ltd. (ZURA)

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001855644

Zura Bio Ltd. ZURA; healthcare		
Grade	None 5 of 14 inputs computable; 7 are required	Share price, twelve months to the rescan split-adjusted close; the letter is fixed at the rescan that set it 
Reliability	0.83 AUC filers with \$12.5M to \$120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025	
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025	
Size band	\$12.5M to \$120M assets total assets \$113.9M	
Warnings	dilution, thin data not computable: degenerate inputs, distress, fortress balance sheet	
Inputs computable	5 of 14	
Graded from	filings received through Mar 19, 2026 204 days before the rescan; latest periodic filing 10-Q received Aug 11, 2026	
Last close	\$4.12 2026-10-08; market equity \$394.3M	
Price used in grade	None	

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only

A	
B	
C	
D	
E	
	20132014201520162017201820192020202120222023202420252026

Business, in the company's words

opening of Item 1 of the 10-K received Mar 19, 2026

We are a clinical-stage biotechnology company developing novel and differentiated medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with significant unmet medical need. These diseases are often chronic, biologically complex and difficult to treat, and many patients do not achieve durable disease control with currently available therapies. Our strategy is to identify immune-mediated diseases in which translational and clinical evidence supports the role of specific biological pathways in disease pathogenesis.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 73.5						
Gross profitability		not computable	32.2%		one or more required annual facts are missing	

Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(2.6%)	(6.6%)	73.5	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 0
Solvency, sleeve percentile 21.2						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		3.48	(0.31)	23.8	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			one or more required annual facts are missing
Current ratio		9.05x	2.96x	18.6	839	2025-12-31
Growth and financing, sleeve percentile 36.5						
Revenue growth, three-year compound		not computable	10.0%			four annual observations are required; found 0
Free cash flow growth, three-year compound		not computable	10.9%			four consecutive annual FCF observations are required; found 2
Reinvestment rate		not computable	37.1%			NOPAT must exceed \$100,000
Asset growth, three years		178.7%	2.1%	0.7	704	2025-12-31
Net share issuance, one year		38.8%	2.5%	72.4	634	2026-03-16

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 38.8%
Thin data	5 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	27.9%	8.0%	64
Distance from 52-week high	(41.3%)	(31.4%)	37
EBIT to enterprise value	not computable	(1.5%)	

Free cash flow yield	(16.4%)	(1.0%)	24
Book value to price	0.50	0.28	69
Sales to price	not computable	0.31	
Composite equity issuance, five years	not computable	20.3%	
Relative strength against the sector, log excess return	0.03	(0.14)	64

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$205.1M
Operating cash flow, four quarters	-\$64.8M
Months of runway	38.0
Days since last periodic filing	59 (10-Q received Aug 11, 2026)
Median daily dollar volume, 63 sessions	\$6.0M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-\$68.7M	2025-12-31	2026-03-19	10-K	0001104659-26-032080
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$64.8M	2025-12-31	2026-03-19	10-K	0001104659-26-032080
3	assets	us-gaap:Assets	\$113.9M	2025-12-31	2026-03-19	10-K	0001104659-26-032080
4	assets	us-gaap:Assets	\$179.5M	2024-12-31	2026-03-19	10-K	0001104659-26-032080
5	current assets	us-gaap:AssetsCurrent	\$112.3M	2025-12-31	2026-03-19	10-K	0001104659-26-032080
6	current liabilities	us-gaap:LiabilitiesCurrent	\$12.4M	2025-12-31	2026-03-19	10-K	0001104659-26-032080
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$224.5M	2025-12-31	2026-03-19	10-K	0001104659-26-032080
8	operating income	us-gaap:OperatingIncomeLoss	-\$75.2M	2025-12-31	2026-03-19	10-K	0001104659-26-032080
9	book equity	us-gaap:StockholdersEquity	\$101.5M	2025-12-31	2026-03-19	10-K	0001104659-26-032080
10	liabilities	us-gaap:Liabilities	\$12.4M	2025-12-31	2026-03-19	10-K	0001104659-26-032080
11	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$75,000	2024-12-31	2026-03-19	10-K	0001104659-26-032080
12	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$9,000	2024-12-31	2026-03-19	10-K	0001104659-26-032080
13	operating income	us-gaap:OperatingIncomeLoss	-\$55.2M	2024-12-31	2026-03-19	10-K	0001104659-26-032080
14	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsAndControllingInterests	\$54.1M	2025-12-31	2026-03-19	10-K	0001104659-26-032080
15	income tax	us-gaap:IncomeTaxExpenseBenefit	\$0	2024-12-31	2025-03-25	10-K	0001410578-25-000443
16	current assets	us-gaap:AssetsCurrent	\$178.7M	2024-12-31	2026-03-19	10-K	0001104659-26-032080
17	current liabilities	us-gaap:LiabilitiesCurrent	\$19.5M	2024-12-31	2026-03-19	10-K	0001104659-26-032080
18	current assets	us-gaap:AssetsCurrent	\$100.8M	2023-12-31	2025-03-25	10-K	0001410578-25-000443
19	current liabilities	us-gaap:LiabilitiesCurrent	\$20.3M	2023-12-31	2025-03-25	10-K	0001410578-25-000443
20	assets	us-gaap:Assets	\$100.8M	2023-12-31	2025-03-25	10-K	0001410578-25-000443
21	assets	us-gaap:Assets	\$5.3M	2022-12-31	2024-03-28	10-K	0001410578-24-000329
22	shares outstanding	dei:EntityCommonStockSharesOutstanding	94,880,710	2026-03-16	2026-03-19	10-K	0001104659-26-032080
23	shares outstanding	dei:EntityCommonStockSharesOutstanding	68,374,998	2025-03-21	2025-03-25	10-K	0001410578-25-000443